The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype

Gastrosplenic Fistula From Hodgkin's Lymphoma

(2009) Carolyn D. Seib et al.   JOURNAL OF CLINICAL ONCOLOGY

Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics

(2009) David R. Gandara et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Gemcitabine Plus Docetaxel Compared With Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast Cancer

(2009) Stephen Chan et al.   JOURNAL OF CLINICAL ONCOLOGY

Colorectal Hepatic Metastases: Adjuvant Chemotherapy and Survival

(2009) David J. Gallagher et al.   JOURNAL OF CLINICAL ONCOLOGY

Triple-negative breast cancer: Novel therapies and new directions

(2009) Sumanta Kumar Pal et al.   MATURITAS

Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer

(2008) S. L. Hines et al.   ANNALS OF ONCOLOGY

Clinical Interpretation of Quality-of-Life Outcomes: An Investigation of Data from the Randomized Trial of Gemcitabine Plus Paclitaxel Compared with Paclitaxel Alone for Advanced Breast Cancer

(2008) Penelope Hopwood et al.   Breast Journal

Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer

(2008) Nancy U. Lin et al.   CANCER

Beyond Cytotoxic Chemotherapy for the First-Line Treatment of HER2-Negative, Hormone-Insensitive Metastatic Breast Cancer: Current Status and Future Opportunities

(2008) Alison K. Conlin et al.   Clinical Breast Cancer

Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment

(2008) Kathy S. Albain et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

(2008) Andrew D. Seidman et al.   JOURNAL OF CLINICAL ONCOLOGY